TP53 mutants in the tower of babel of cancer progression

Human Mutation

Volumn 35, Issue 6, 2014, Pages 689-701

  Bisio, Alessandra ^a   Ciribilli, Yari ^a   Fronza, Gilberto ^b   Inga, Alberto ^a   Monti, Paola ^b  

^a UNIVERSITY OF TRENTO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer; Gain of function; Li Fraumeni; P53; TP53; Transactivation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INHIBITOR OF DIFFERENTIATION 2; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PROTEIN P63; PROTEIN P73; PUMA PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; AMINO ACID SEQUENCE; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; DATA BASE; DNA BINDING; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; FAMILIAL CANCER; GAIN OF FUNCTION MUTATION; GERMLINE MUTATION; HUMAN; IN VITRO STUDY; LIPID METABOLISM; METASTASIS; MISSENSE MUTATION; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OLIGOMERIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; REVIEW; UPREGULATION; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY;

ANIMALIA;

DATABASES, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901189286     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22514     Document Type: Review

References (153)

1. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, et al. 2009. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87-98.
2. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, et al. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402.
3. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. 2006. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25:304-309.
4. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD. 1998. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 17:1847-1859.
5. Brazdova M, Navratilova L, Tichy V, Nemcova K, Lexa M, Hrstka R, Pecinka P, Adamik M, Vojtesek B, Palecek E, Deppert W, Fojta M. 2013. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. PLoS One 8:e59567.
6. Brosh R, Rotter V. 2009. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701-713.
7. Campion CG, Labrie M, Lavoie G, St-Pierre Y. 2013. Expression of Galectin-7 is induced in breast cancer cells by mutant p53. PLoS One 8:e72468.
8. Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G. 2001. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20:3573-3579.
9. Chene P, Bechter E. 1999. p53 mutants without a functional tetramerisation domain are not oncogenic. J Mol Biol 286:1269-1274.
10. Chin KV, Ueda K, Pastan I, Gottesman MM. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462.
11. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
12. Ciribilli Y, Andreotti V, Menendez D, Langen JS, Schoenfelder G, Resnick MA, Inga A. 2010. The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One 5:e10236.
13. Ciribilli Y, Monti P, Bisio A, Nguyen HT, Ethayathulla AS, Ramos A, Foggetti G, Menichini P, Menendez D, Resnick MA, Viadiu H, Fronza G, et al. 2013. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Nucleic Acids Res 41:8637-8653.
14. Coffill CR, Muller PA, Oh HK, Neo SP, Hogue KA, Cheok CF, Vousden KH, Lane DP, Blackstock WP, Gunaratne J. 2012. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep 13:638-644.
15. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. 1999. p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53. The J Biol Chem 274:18709-18714.
16. de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 99:2948-2953.
17. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G. 2006. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10:191-202.
18. Di Como CJ, Gaiddon C, Prives C. 1999. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19:1438-1449.
19. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. 1993. Gain of function mutations in p53. Nat Genet 4:42-46.
20. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, Li R, Martinez LA. 2012. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26:830-845.
21. Donehower LA. 2014. Insights into wildtype and mutant p53 functions provided by genetically engineered mice. Hum Mutat 35:715-727.
22. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N. 2013. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32:3286-3295.
23. Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. 2008. Oncogenomic approaches in exploring gain of function of mutant p53. Curr Genomics 9:200-207.
24. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. 2012. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19:1038-1048.
25. Dotsch V, Bernassola F, Coutandin D, Candi E, Melino G. 2010. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2:a004887.
26. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat Genet 1:45-49.
27. Ethayathulla AS, Tse PW, Monti P, Nguyen S, Inga A, Fronza G, Viadiu H. 2012. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci USA 109:6066-6071.
28. Fontemaggi G, Dell'Orso S, Muti P, Blandino G, Strano S. 2010. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle 9:2464-2466.
29. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, et al. 2009. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16:1086-1093.
30. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. 1998. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18:3735-3743.
31. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, et al. 2012. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244-258.
32. Freed-Pastor WA, Prives C. 2012. Mutant p53: one name, many proteins. Genes Dev 26:1268-1286.
33. Friedlander P, Legros Y, Soussi T, Prives C. 1996. Regulation of mutant p53 temperature-sensitive DNA binding. J Biol Chem 271:25468-25478.
34. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. 2001. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21:1874-1887.
35. Garritano S, Inga A, Gemignani F, Landi S. 2013. More targets, more pathways and more clues for mutant p53. Oncogenesis 2:e54.
36. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, et al. 2011. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20:79-91.
37. Goh AM, Coffill CR, Lane DP. 2011. The role of mutant p53 in human cancer. J Pathol 223:116-126.
38. Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V. 2012. p53, a novel regulator of lipid metabolism pathways. J Hepatol 56:656-662.
39. Green DR, Kroemer G. 2009. Cytoplasmic functions of the tumour suppressor p53. Nature 458:1127-1130.
40. Gurtner A, Fuschi P, Martelli F, Manni I, Artuso S, Simonte G, Ambrosino V, Antonini A, Folgiero V, Falcioni R, Sacchi A, Piaggio G. 2010. Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation. Cancer Res 70:9711-9720.
41. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. 2013. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20:898-909.
42. Hassan NM, Tada M, Hamada J, Kashiwazaki H, Kameyama T, Akhter R, Yamazaki Y, Yano M, Inoue N, Moriuchi T. 2008. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. Cancer Lett 270:108-119.
43. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y. 2009. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 69:4818-4826.
44. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134.
45. Hu J, Liu Z, Wang X. 2013. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? Med Hypotheses 81:515-520.
46. Huang X, Wu Z, Mei Y, Wu M. 2013. XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. EMBO J 32:2204-2216.
47. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, Sidransky D, Ratovitski E. 2011. Phospho-DeltaNp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 18:1220-1230.
48. Inga A, Monti P, Fronza G, Darden T, Resnick MA. 2001. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20:501-513.
49. Inga A, Resnick MA. 2001. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20:3409-3419.
50. Jagosova J, Pitrova L, Slovackova J, Ravcukova B, Smarda J, Smardova J. 2012. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells. Int J Oncol 41:1157-1163.
51. Joerger AC, Rajagopalan S, Natan E, Veprintsev DB, Robinson CV, Fersht AR. 2009. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci USA 106:17705-17710.
52. Jones M, Lal A. 2012. MicroRNAs, wild-type and mutant p53: more questions than answers. RNA Biol 9:781-791.
53. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, Resnick MA. 2010. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res 8:701-716.
54. Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA, Resnick MA. 2008. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 4:e1000104.
55. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
56. Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, et al. 2012. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J Cell Sci 125(Pt 22):5578-5586.
57. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424-8429.
58. Kim E, Deppert W. 2003. The complex interactions of p53 with target DNA: we learn as we go. Biochem Cell Biol 81:141-150.
59. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z. 2006. Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741-753.
60. Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, Honig B, Shakked Z. 2010. Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol 17:423-429.
61. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, et al. 2012. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 40:499-510.
62. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, et al. 2011. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 18:271-281.
63. Kong XT, Gao H, Stanbridge EJ. 2001. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function. J Biol Chem 276:32990-3000.
64. Lane D, Levine A. 2010. p53 research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2:a000893.
65. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872.
66. Leith JS, Tafvizi A, Huang F, Uspal WE, Doyle PS, Fersht AR, Mirny LA, van Oijen AM. 2012. Sequence-dependent sliding kinetics of p53. Proc Natl Acad Sci USA 109:16552-16557.
67. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. 2013. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 41(Database issue):D962-D969.
68. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. 2012. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269-1283.
69. Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, Johnson E, Lal B, Hussaini I, Bao Y, Laterra J, Schiff D, et al. 2008. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res 68:1723-1731.
70. Lin J, Teresky AK, Levine AJ. 1995. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10:2387-2390.
71. Liu DP, Song H, Xu Y. 2010. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29:949-956.
72. Liu K, Ling S, Lin WC. 2011. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 31:4464-4481.
73. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR. 2013. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:6034-6044.
74. Lozano G. 2010. Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2:a001115.
75. Ludwig RL, Bates S, Vousden KH. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16:4952-4960.
76. Macedo GS, Lisboa da Motta L, Giacomazzi J, Netto CB, Manfredini V, Vanzin CS, Vargas CR, Hainaut P, Klamt F, Ashton-Prolla P. 2012. Increased oxidative damage in carriers of the germline TP53 p.R337H mutation. PLoS One 7:e47010.
77. Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. 2013. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS One 8:e61353.
78. Malkin D. 2011. Li-fraumeni syndrome. Genes Cancer 2:475-484.
79. Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada J, Asaka M, Moriuchi T. 1999. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59:4765-4769.
80. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G. 2013. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene.
81. Melino G. 2011. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 18:1487-1499.
82. Menendez D, Inga A, Resnick MA. 2006. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 26:2297-2308.
83. Menendez D, Inga A, Resnick MA. 2009. The expanding universe of p53 targets. Nat Rev Cancer 9:724-737.
84. Menendez D, Inga A, Resnick MA. 2010. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci USA 107:1500-1505.
85. Menendez D, Inga A, Snipe J, Krysiak O, Schonfelder G, Resnick MA. 2007. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol 27:2590-2600.
86. Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R, Resnick MA. 2013. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res 41:7286-7301.
87. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550-13555.
88. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, Cordenonsi M, Piccolo S. 2012. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487:380-384.
89. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G. 2003. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22:5252-5260.
90. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, Resnick MA, Fronza G. 2002. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene 21:1641-1648.
91. Monti P, Ciribilli Y, Jordan J, Menichini P, Umbach DM, Resnick MA, Luzzatto L, Inga A, Fronza G. 2007. Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res 13:3789-3795.
92. Monti P, Perfumo C, Bisio A, Ciribilli Y, Menichini P, Russo D, Umbach DM, Resnick MA, Inga A, Fronza G. 2011. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol Cancer Res 9:271-279.
93. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, et al. 2009. Mutant p53 drives invasion by promoting integrin recycling. Cell 139:1327-1341.
94. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, et al. 2013. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32:1252-1265.
95. Muller PA, Vousden KH, Norman JC. 2011. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192:209-218.
96. Natan E, Hirschberg D, Morgner N, Robinson CV, Fersht AR. 2009. Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci USA 106:14327-14332.
97. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF. 2013. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 32:2992-3000.
98. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. 2011. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2:1203-1217.
99. Nguyen T-A, Menendez D, Resnick MA, Anderson CW. 2014. Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat 35:738-755.
100. Nicholls CD, McLure KG, Shields MA, Lee PW. 2002. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 277:12937-12945.
101. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, Selivanova G. 2012. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 19:1992-2002.
102. Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM. 2012. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 31:2836-2848.
103. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860.
104. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, et al. 2006. The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin Cancer Res 12:1157-1167.
105. Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2:a001107.
106. Pantziarka P. 2013. Li Fraumeni syndrome, cancer and senescence: a new hypothesis. Cancer Cell Int 13:35.
107. Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, Graessmann A, Ogryzko V, Pishvaian M, Albanese C, Avantaggiati ML. 2010. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol 225:394-405.
108. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629.
109. Quante T, Otto B, Brazdova M, Kejnovska I, Deppert W, Tolstonog GV. 2012. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 11:3290-3303.
110. Reinhardt HC, Schumacher B. 2012. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 28:128-136.
111. Resnick MA, Inga A. 2003. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100:9934-9939.
112. Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
113. Robles AI, Harris CC. 2010. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2:a001016.
114. Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH, Iggo R. 1999. Increased apoptosis induction by 121F mutant p53. EMBO J 18:4424-4437.
115. Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, Vogiatzi F, Leich E, Samans B, Eilers M, Kisker C, Rosenwald A, et al. 2010. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 38:356-368.
116. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, Wagner T, Reichardt S, von Werder A, Schmid RM, Weih F, Heinzel T, et al. 2010. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 29:2795-2806.
117. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. 2005. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25:10097-10110.
118. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. 2004. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 64:7447-7454.
119. Shakked Z. 2007. Quaternary structure of p53: the light at the end of the tunnel. Proc Natl Acad Sci USA 104:12231-12232.
120. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. 2004. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279:348-355.
121. Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A, Nanda S, Druker H, Scherer SW, Malkin D. 2008. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA 105:11264-11269.
122. Silva JL, Rangel LP, Costa DC, Cordeiro Y, De Moura Gallo CV. 2013. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep 33.
123. Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldfinger N, Rotter V. 2012. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci 125(Pt 13):3144-3152.
124. Song H, Hollstein M, Xu Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580.
125. Soussi T. 2014. Locus-specific databases in cancer: What future in a post-genomic Era? The TP53 LSDB paradigm. Hum Mutat 35:643-653.
126. Soussi T. 2011. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 110:107-139.
127. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, et al. 2010. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17:273-285.
128. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. 2010. TAp63 suppresses metastasis through coordinate regulation of dicer and miRNAs. Nature 467:986-990.
129. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. 2012. The p53 circuit board. Biochim Biophys Acta 1825:229-244.
130. Tabori U, Nanda S, Druker H, Lees J, Malkin D. 2007. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 67:1415-1418.
131. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. 2008. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22:1337-1344.
132. Trkova M, Prochazkova K, Krutilkova V, Sumerauer D, Sedlacek Z. 2007. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. Cancer 110:694-702.
133. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, et al. 2012. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 109:15312-15317.
134. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S. 2011. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10:4330-4340.
135. Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP, Deb S. 2012. Gain-of-function activity of mutant p53 in lung cancer through up-regulation of receptor protein tyrosine kinase Axl. Genes Cancer 3:491-502.
136. Walerych D, Napoli M, Collavin L, Del Sal G. 2012. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33:2007-2017.
137. Wang B, Niu D, Lai L, Ren EC. 2013a. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun 4:2359.
138. Wang PY, Ma W, Park JY, Celi FS, Arena R, Choi JW, Ali QA, Tripodi DJ, Zhuang J, Lago CU, Strong LC, Talagala SL, et al. 2013b. Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med 368:1027-1032.
139. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, et al. 2009. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11:694-704.
140. Wang W, Cheng B, Miao L, Mei Y, Wu M. 2013c. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis 4:e574.
141. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. 2004. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64:8318-8327.
142. Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. 2012. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One 7:e51426.
143. Will K, Warnecke G, Wiesmuller L, Deppert W. 1998. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proc Natl Acad Sci USA 95:13681-13686.
144. Willis A, Jung EJ, Wakefield T, Chen X. 2004. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23:2330-2338.
145. Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, Herlyn M, Gimotty P, Nakagawa H, Rustgi AK. 2013. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis 2:e59.
146. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, Cornelis A, Rozenski J, Zwolinska A, Marine JC, Lambrechts D, Suh YA, et al. 2011. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7:285-295.
147. Yan W, Chen X. 2010. Characterization of functional domains necessary for mutant p53 gain of function. J Biol Chem 285:14229-14238.
148. Yan W, Liu G, Scoumanne A, Xinbin C. 2008. Suppression of Id2, a member of the inhibitor of differentiation family and a target of mutant p53, is required for mutant p53 gain of function. Cancer Res 68:6789-6796.
149. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.
150. Yasuda K, Kato S, Sakamoto Y, Watanabe G, Mashiko S, Sato A, Kakudo Y, Ishioka C. 2012. Induction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53. Oncol Lett 3:978-982.
151. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, Windle B, Deb S. 2012. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33:442-451.
152. Zerdoumi Y, Aury-Landas J, Bonaiti-Pellie C, Derambure C, Sesboue R, Renaux-Petel M, Frebourg T, Bougeard G, Flaman JM. 2013. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum Mutat 34:453-461.
153. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB. 1994. A temperature-sensitive mutant of human p53. EMBO J 13:2535-2544.